Literature DB >> 1641651

An overview of the clinical experience with hydroxyurea.

R C Donehower1.   

Abstract

In the more than 30 years since hydroxyurea was first evaluated clinically, a number of diverse and unique applications have been identified for its use. Some of these applications were apparent to investigators almost from the beginning, while others are still evolving 3 decades later as a result of ongoing research. An overview of clinical experience with hydroxyurea provides an historical perspective on a period encompassing virtually the entire era in which anticancer chemotherapy has been a recognized discipline. The critical role of the ribonucleotide reductase reaction in the regulation of DNA synthesis makes this enzyme a particularly important target site for antineoplastic therapy. The sustained interest in hydroxyurea, however, has been the result of careful clinical observations as well as basic laboratory studies, which support current attempts to identify additional uses for the drug. This overview describes the clinical development of hydroxyurea, discusses current indications, and briefly describes areas of ongoing research that may expand the clinical indications for hydroxyurea.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1641651

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  32 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.

Authors:  Md Faiz Ahmad; Sarah E Huff; John Pink; Intekhab Alam; Andrew Zhang; Kay Perry; Michael E Harris; Tessianna Misko; Suheel K Porwal; Nancy L Oleinick; Masaru Miyagi; Rajesh Viswanathan; Chris Godfrey Dealwis
Journal:  J Med Chem       Date:  2015-12-09       Impact factor: 7.446

4.  Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.

Authors:  Md Faiz Ahmad; Intekhab Alam; Sarah E Huff; John Pink; Sheryl A Flanagan; Donna Shewach; Tessianna A Misko; Nancy L Oleinick; William E Harte; Rajesh Viswanathan; Michael E Harris; Chris Godfrey Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

5.  An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis.

Authors:  M J Starmans-Kool; M M Fickers; M A Pannebakker
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

6.  Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

7.  Mutagenicity of new lead compounds to treat sickle cell disease symptoms in a Salmonella/microsome assay.

Authors:  Jean Leandro dos Santos; Eliana A Varanda; Lídia Moreira Lima; Chung Man Chin
Journal:  Int J Mol Sci       Date:  2010-02-25       Impact factor: 5.923

8.  Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.

Authors:  W Y Gao; A Cara; R C Gallo; F Lori
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

9.  A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.

Authors:  J J Beitler; R V Smith; H Haynes; C E Silver; A Quish; T Kotz; M Serrano; A Brook; S Wadler
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.

Authors:  S D Malley; J M Grange; F Hamedi-Sangsari; J R Vila
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.